Note: Descriptions are shown in the official language in which they were submitted.
~2~393 67854-~
COLLAGEN INHIBITING COMPOSITIONS AND PROCESSES
FOR MANUFACTURING AND USING SAME
Field of the Invention
This invention relates to pharmaceutical compositions
and processes for manufacturing same, and more particularly to the
manufacture and use of certain analogs of the amino acid praline
in complex polymeric form for controlling the cellular synthesis
of scars and fibrous tissue in animals.
Background of the Invention
Collagen is a protein which occurs naturally in all
animals in the form of tough fibers. Such collagen fibers are in
effect the "glue" holding together the tissues of the body.
Collagen is synthesized by many cells from certain amino acid
including the amino acid praline. Collagen-producing cells are
located primarily in the skin, bone, tendons, ligaments, nerves,
cartilage and blood vessels of animals and collagen fibers are
formed whenever tissue is damaged, in the sense that deposition
of collagen fibers is a normal part of the process of tissue
repair. In certain instances, however, excessive amounts of
collagen are produced, with substantial, undesirable results.
In particular, scar formation in the hying of wounds, from
trauma or disease, or following surgery, is a result of excessive
production of collagen, since the major constituent of scar
tissue is collagen.
The development of large, unsightly masses of scar
tissue may produce physiological problems in human beings, and
may interfere substantially with the normal physical and
biological function of organs and tissues. For example, after
surgery to the abdomen, the formation of excessive scar tissue
or "adhesions" around abdominal organs, such as the intestines,
I'
aye
67854-~
often interferes with the functionality of such organs and may
cause severe pain and even death. After hand surgery, the
formation of excessive scar tissue around the tendons of the
wrist or hand often prevents normal functioning of the hand.
After surgery to the back, excessive scar tissue around the
spinal nerves may produce severe pain and limitation of motion.
After plastic surgery to the face the formation of excessive
scar tissue may frequently compromise the benefits of the
surgery.
-lo-
,,
1239393
In horses, a condition known as "proud flesh" often occurs. It
is an excessive build-up of scar tissue and when occurring near a
leg joint may interfere considerably with the use of the legs
for heavy work or for racing. Similar excessive build-up of
scar tissue may also occur in horses when leg tendons are sun-
glcally repaired.
It is, therefore, desirable to be able to control or
limit the amount of collagen formed and released by the collagen-
producing cells in specific body areas for limited periods of
time. However, in controlling the synthesis and deposition of
collagen fibers, it is extremely important not to interfere with
the cellular production of other protein necessary for normal
body functioning.
In Belgium Patent No. 784,650, there is disclosed the
use of free praline analogs in a pharmaceutically acceptable
carrier for controlling collagen formation The use of such
praline analog exhibited some efficacy in reducing scar tissue
formation, however, the benefit was at best minimal such free
praline analogs are not susceptible to topical application about
a wound, since topical application results in an edematous
condition, i.e. the accumulation of fluid with concomitant
symptoms of pain and swelling. Further, free praline analogs are
water soluble and readily absorbed thereby entering the circular
lion system.
Objects of the Invention
An object of the present invention is to provide a
novel composition including in polymeric form select analogs of
praline for limiting and controlling collagen synthesis.
Another object of the present invention is the topical
application of an effective amount of a novel composition in-
eluding in polymeric form select analogs of praline for limiting
and controlling collagen synthesis.
-2-
393
Yet another object of the present invention is to
provide a process for preparing a novel composition including in
polymeric form select analogs of praline for limiting and
controlling collagen synthesis.
Still another object of the present invention is to
provide novel collagen-inhibiting compositions including in
polymeric form select analogs of praline for localized
-pa-
lZ39393
67854-4
application to animals for the purpose of limiting and
controlling the synthesis and deposition of collagen fibers.
A still further object of the present invention is to
provide a method for the prevention and control of certain
conditions in animals involving the excessive synthesis and
deposition of collagen fibers comprising the administration of an
effective amount of a collagen-inhibiting composition including
in polymeric form select praline analogs.
Yet another object of the present invention is to
provide certain collagen inhibiting compositions and methods to
be used in treating animals to control and limit scar tissue
formation due to wounds from trauma, including burns or diseases,
after surgery for the treatment of those diseases involving
fibrosis, with excessive accumulations of collagen, such as
pulmonary fibrosis, etc.
Summary of the Invention
These and other objects of the present invention are
achieved by the use of a collagen-inhibiting composition include
in in polymeric form select analogs of praline and processes
for the manufacture and use of such a collagen-inhibiting
composition.
Detailed Description of the Present Invention
As used herein, the term "quasi-collagen" means a
collagen-like protein molecule which includes a praline analog,
at one or more of the sites at which praline or trans-4-hydroxy-
L-proline would normally be found in collagen.
As used herein, the term "animals" includes human
beings. As used herein, the term "polymers" includes compounds
of large molecular weight and which consists of praline analogs
together with amino acids or similar compounds, linked to each
--3--
1~393 67854-4
other by peptize bonds, ester bonds, or other covalent bonds.
While not fully understood, it is believed that the
topical use of such a collagen-inhibiting composition including
in polymeric form select praline analogs of the present invention,
such as the application of such composition is powdered form to
the area to be treated, results in the gradual decomposition of
such a polymeric praline analog composition through the action of
either water found in the tissue fluids, or through the action
of degradative enzymes naturally present in tissue fluids. In
the course of decomposing, such a collagen-inhibiting composition
releases one or more praline analogs, together with other
compounds with have no appreciable biological effects. The thus
released praline analog or praline analogs will be taken upon
by the collagen-producing cells in the area and will be incorp-
orated into some of the collagen molecules synthesized within
the cell to form "quasi-collagen" molecules. Of the 3,000 amino
acids which are incorporated into a single normal collagen
molecule, about 600 of the amino acid sites are occupied by
praline and by trans-4-hydroxy-L-proline, an amino acid form
from praline during the synthesis of collagen.
Accordingly, when a praline analog is administered
into the collagen-producing cells "quasi-collagen" molecules are
synthesized by the cells incorporating the praline analog at
certain sites at which praline or trans-4-hydroxy-L-proline is
normally present in a collagen-molecule. The number of sites at
which the praline analog is present will vary from a few sites
in each molecule to more than one-half of the available praline
or trans-4-hydroxy-L-proline sites. These "quasi-collagen"
molecules do not have the normal three-dimensional conformation
of normal collagen and therefore cannot be used by the cells and
1~393 67854-4
tissues to assemble collagen fibers. Therefore, the net
effect of incorporation of the praline analogs is to inhibit
synthesis of collagen fibers. The duration of such inhibition
of collagen formation depends on such factors as the particular
praline analog administered, the quantity administered, the rate
at which the praline analog is released from the collagen-
inhibiting composition, and the frequency of dosage repetition.
The inhibition of the formation of collagen fibers by
the synthesis of the "quasi-collagen" is believed to occur for
the following reasons. In a normal collagen molecule, the amino
acids praline and trans-4-hydroxy-L-proline account for
approximately 20~ of the total amino acid composition. The
presence of praline and trans-4-hydroxy-L-proline in the three
palpated chains which comprise the collagen molecule is
apparently essential for the three chains to fold into a helical,
rope-like three-dimensional structure of the normal collagen
molecule, Incorporation of praline analogs into the collagen
molecule in sites normally occupied by praline and trueness-
hydroxy-proline residues prevents the three palpated chains
from assuming the normal helical conformation, for one or two
reasons. One reason is that the praline analogs, because of
incorrect steno or chemical structure, do not allow the three
palpated chains to come together correctly. The second
reason is that, with several praline analogs, the presence of
the praline analogs in the palpated chains prevent the normal
conversion of specific praline residues to trans-4-hydroxy-L-
praline residues by the action of an enzyme normally present in
collagen-synthesizing cells. Because the conversion of praline
to trans-4-hydroxy-L-proline does not occur to an adequate
extent, the three palpated chains cannot form a helical
-5-
1239393 67854-4
structure which is stable under normal body conditions. Since
the cells synthesize "quasi-collagen" instead of normal collagen,
the production of collagen molecules used to form fibers is
marketedly reduced.
The praline analogs which are useful in the practice of
the present invention include the cis-isomer of praline analogs
having is- and trays- isomers, and not the transisomers; and
the Levi isomers of praline analogs, and not the dexter
isomers or non-optical isomers, except where the DO form is
required to be used since the L form cannot be economically
isolated.
Praline analogs of the present invention include the
is- and Levi isomers of the compounds of the general strut-
tubal formula H H
I COO
wherein R is OH, Of, F, SHEA, NH3, OKAY, OC(OH)CH2, CH3,SH, SHEA, OUCH, ONE, OOZE, H2P04, or COO; L-pipecolic
acid; 1,2,3,6-tetrahydro-L-picolinic acid; 1,2,3,4-tetrahydro-
L-picolinic acid; 1,4,5,6-tetrahydro-L-picolinic acid; 1,2,5,
6-tetrahydro-L-picolinic acid; and 1,2-dihydro-L-picolinic acid;
the Levi isomers of the compound of general structural formula
X
N COO
H
IX
I COO
H
ON COO
H
. ,
123,.9393
67854-4
where X is N, S or O; L-azetidine-2-carboxylic acid, 3,4-
dehydro-L-proline and 4,5-dehyrdro-L-proline.
The praline analogs which are preferred for use in a
collagen-inhibiting composition of the present invention are
L-azetidine-2-carboxylic acid, cis-4-fluoro-L-proline, 3,4-
dehydro-L-proline, cis-4-hydroxy-L-proline and cis-4-chloro-L-
praline with cis-4-hydroxy-L-proline being most preferred.
The praline analogs are employed in a collagen-inhibit-
in composition in which the praline analog is chemically linked
into a large molecular structure and from which the praline
analog is slowly released when the composition is topically
applied. One collagen-inhibiting composition consists of a
polymer of cis-hydroxy-L- praline chemically linked to itself
by ester bonds resulting in a large molecular structure of the
formula: _ _
-Ox
KIWI-
H
_ _ n
Another composition consists of palpated chains of amino acid
to which a praline analog is linked through the carboxyl group
of the praline analog to form an ester linked to a hydroxyl
group of a palpated chain. For example, a polymeric
structure given by the structural formula:
Shipley
-Ala-cHyp-Gly-
1~9393 67854-4
where chop is cis-4-hydroxy-L-proline, Ala is L-alanine and
Guy is Gleason.
It is important to note that the compositions include
in the praline analogs of the present invention are of large
molecular weight and thereby will not readily leave the site
in or on administered tissues. Also the collagen-inhibiting
compositions do not have strong osmotic effects as might be
obtained with small molecular weight compounds, such as praline
analogs, per so. It is important to note that the polymers
hydrolyzed by the action of water per so, or by the action of
water in the presence of naturally occurring tissue enzymes,
to slowly release the praline analog to the collagen-producing
cells. The controlled release of the praline analog in such
manner permits the administering of large concentrations of the
praline analog at the site where its action is required.
As a praline analog is released from the polymer
composition and diffuses from the administered site, the
praline analog is rapidly diluted by body fluids and its
concentration diminished. Therefore, tissues or sites other
than the administered site are exposed to much lower convent-
rations of the praline analog and thereby markedly diminish
any possible deleterious effects on other tissues. Thus,
the use of the collagen-inhibiting composition of the present
invention functions to modulate the production of collagen
fibers by collagen-producing cells within given sites of animals.
The mechanism of "quasi-collagen" formation, while
significantly curtailing for a period of time the synthesis of
collagen and collagen fibers by individual collagen-producing
cells, does not interfere with the production of other proteins
I by these same cells or by non-collagen-producing cells. This is
~39393 67854-4
very important for the effective functioning for limiting or for
the controlled production of collagen since in the usual
situation, agents interfering with the synthesis of protein
by one type of animal cell in one site within a tissue will
interfere with a synthesis of all proteins in all the tissues
of the animal, thereby producing a wide range of systemic
effects, many of which can be harmful.
As is hereinafter more fully discussed, the collagen-
inhibiting compositions of the instant invention have efficacy
in inhibiting formation of fibrous tissue in laboratory animals,
and are therefore considered to be useful in controlling the
formation of scar tissue in wounds, caused by trauma, disease,
or surgical-incisions in animals, while permitting growth of
normal tissues. In the use of the disclosed collagen-inhibiting
compositions to prevent scar tissue formation, a limited amount
of the collagen-inhibiting compositions of the present invention
are locally applied in a single application, or for a limited
period of time, until a significant healing of the tissue has
occurred, after which no further application of the collagen-
inhibiting composition is necessary. The use of a collagen-
inhibiting composition of the present invention to prevent scar
formation, does not necessarily terminate the synthesis of
collagen fibers by collagen-producing cells. Rather, by the
proper control of dosage amount and dosage frequency, the
collagen-producing cells can be permitted to continue.tosynthesize
limited amounts of collagen for normal tissue-adhesive function.
Controlling scar formation has particular application
to humans and several other species of animals, the members of
which have a tendency to excessive collagen accumulation in the
form of scars at sites of wounds, surgical incisions, or tissue
~2393~3
67854-4
damage produced by a variety of agents. The application
includes especially certain racial groups amount humans, having
a genetic tendency to killed formation at the sites of wounds or
incisions. The collagen-inhibiting compositions may be utilized
for the prevention of excessive deposition of collagen in
diseased conditions in which non-collagenous tissues are replaced
by collagen. An example of the excessive deposition of collagen
in certain disease conditions to which the collagen-inhibiting
compositions of the present invention are applicable is lung
fibrosis, a condition caused by inhalation of foreign materials
such as silica or asbestos, or as occurs in older persons from
unknown causes. In such instances, where a lung fibrosis is
commencing, further progression is prevented by administration of
the collagen-inhibiting compositions in the form of aerosols. In
other instances the collagen-inhibiting compositions are applied
directly to the site at which control of collagen deposition
and scarring is desired.
As hereinabove described, the most preferred praline
analog for use in the collagen-inhibiting composition, is
cis-4-hydroxy-L-proline. Cis-4-hydroxy-L-proline is commercially
available in limited quantities and is naturally present, e.g.
extractable from the leaves and pericarp of species of
sandalwood tree, Tantalum album, common to India. Cis-4-hydroxy-
L-proline is found in these leaves in the natural form and is
capable of being extracted by the processing disclosed in 80
Biochemical Journal 378 (1961) and 58 Biochemical Journal 57
(1954). Cis-4-fluoro-L-proline may be synthesized by the
procedures disclosed in 4 Biochemistry 2507 (1965). L-azetidine-
2-earboxylie acid may be extracted from the leaves of Lily-of-
the Valley by the procedure disclosed in 64 Biochemical Journal
--10--
~393 67854-4
323 (1956). 3,4-Dehydro-L-proline may be synthesized by the
procedure disclosed in 84 journal of the American Chemical
Society 1967 (1962~.
There follows certain examples which illustrate in
detail the process of this invention for the purpose of
controlling the synthesis of collagen fibers-in animals, as well
as procedures for preparing a number of representative dosage
forms thereof.
EXAMPLE 1
To demonstrate the effectiveness of the collagen-
inhibiting compositions herein described, a test system consist-
in of cells from normal human skin is employed. The principle
of the test system is that when collagen-producing cells, such
as normal skin fibroblasts are introduced into a plastic flask
containing a nutrient medium, the cells attach to the surface of
the flask and grow. However, firm attachment of normal fibre-
blasts to the surface of the flask requires that the cells
first synthesize a "pad" comprised of collagen fibers and
several other materials through which the collagen producing
cells attach to the plastic surface. If synthesis of normal
collagen fibers is prevented, the collagen-producing cells,
such as the normal skin fibroblasts, will not attach and there-
fore will not grow. In the present test system, cis-4-hydroxy-
L-proline prevents attachment and growth of normal fibroblasts
since cis-4-hydroxy-L-proline promotes the synthesis of "quasi-
collagen". The manner in which cis-4-hydroxy-L-proline
produces these effects has been disclosed in 336 Biochimica et
Biophysics Act 234, (1974); 174 Archives of Biochemistry and
B physics 381 (1976); 266 Nature 63 (1977); and 272
Nature 622 (1978).
--11--
<, !,
lZ39393 67854-4
The following three polymeric collagen-inhibiting
compositions of the present invention are tested: Shea,
a polyester of cis-4-hydroxy-L-proline prepared by the polyp
merization of an active ester of a divester of cis-4-hydroxy-L-
praline; Shea, a polyester of cis-4-hydroxy-proline prepared
by the polymerization of an active ester; and crag, a polymer
in which cis-4-hydroxy-L-proline is ester-linked to Swiss-
hydroxy-L-proline in a palpated chain formed from Swiss-
hydroxy-L-proline, ala nine and Gleason.
None of the three polymeric compositions are soluble
in water and are consequently dissolved in 50% acetic acid and
water. The solution is placed drops on a microscopic cover-
slip and the solvent evaporated with warm air from a hair dryer.
The cover slip, coated with the composition, is then placed in a
plastic culture flask (75 cm2; Falcon). From 5xlO to 10.5
x 105 normal human fibroblasts in 2 ml of cell culture medium
are added to the flask. The flask is incubated at 37 C. in 5
carbon dioxide and 95~ air for 3 to 5 days, and the number of
cells in the flask counted. Control sample contained micro-
scopic cover slips treated with an equal volume of solvent and
air-dried.
All three of the compositions inhibited growth of the
fibroblasts. Shea, at a dosage level equivalent to 500 gel
totally prevented growth, and fewer cells are recovered at the
end of the growth period than are initially added to the flask
(Experiment I in Table I). Shea and crag inhibited growth at
dosage levels equivalent to 300 and 500 ~ug/ml (Experiment I and
#3 in Table I).
TABLE I. Effect of Compositions on Collagen Synthesis as Assayed
by Attachment and Growth of Human Skin Fibroblast in Plastic
Culture Flasks
-12-
~23~393
67854-4
Dosage Cells per flask (x 105)
Exit. Level
# Treatment my Initial Final
__
1 None 5.0 67
cis-4-Hydroxy-L-proline 250 5.0 I
Shea 500 5.0 1.0
2 None 10.3 98
cis-4-Hydroxy-L-proline 100 10.3 2.2
Shea 300 10.3 28
Shea 500 10.3 7.0
crag 300 10.3 10.0
3 None 7.0 56
cis-4-Hydroxy-L-proline 50 7.0 12
cis-4-Hydroxy-L-proline 150 7.0 1.3
crag 100 7.0 14.5
crag 300 7.0 7.0
In a parallel series of experiments, cover slips
containing Shea are placed in culture flasks with fibroblasts
under the same conditions. After 1, 2, 3 and 4 days, the over-
slips are removed, and the composition remaining on the coverslipchemically assayed for content of cis-4-hydroxy-L-proline. The
results indicated that the composition disappeared from the
~co~er-slip with a half-life of about 24 hours. Therefore, this
is about the rate at which cis-4-hydroxy-L-proline is released
from the polymer under the conditions of this experiment.
To establish that the effects of the collagen-inhibit-
in compositions are specific for collagen-producing cells,
similar experiments are carried out with a line of cultured cells
-13-
'I
lZ3g393
67854-4
which do not produce collagen. As disclosed in 266 Nature 63
(1977), the growth of such cells is not inhibited by cis-4-hydroxy
-L-proline. Neither the polyester Shea nor the polymer crag
significantly inhibited the growth of the cells (Table II).
Taste II. Effects of Compositions on Attachment and Growth of KB
Cells.
Dosage Cells5per flask
Level (x 10 )
Treatment gel Initial Final
None 8.0 29
Shea 500 8.0 24
crag 500 8.0 27
EXPEL 2
To demonstrate the effectiveness in viva of the forum-
ceutical compositions disclosed here, the polyester Shea is
dissolved in acetic acid and placed dropwiseon polyvinyl sponges.
The solvent is evaporated from the sponges with a hair dryer and
the sponges implanted subcutaneously in rats.
After 4 days, the sponges are removed. Fibrous capsule
had formed around the sponge and the sponge lyophilized and
weighed. As indicated in Table III, 2.5 my owe the polyester
Shea on the sponges did not have a statistically significant
effect on the dry weight of the fibrous capsule. Placing So my
of Shea on the sponge significantly decreased the amount of
fibrous capsule.
-14-
or,
I
~2393~3
67854-4
TABLE III. Effect of a polyester of cis-4-hydroxy-L~proline
in Rats.
Composition # of Dose Weight gain of sponge (my)
placed in rats a) (mg/sponge) Untreated Treated Difference)
sponge
Control 4 28.33 27.17 -1.16
Shea 4 2.5 31.49 29.32 -2.17
Shea 4 5.0 33.75 27.91 -5.84 c)
a) Dry weights of sponges were assayed before and after
implantation. Two sponges were placed in each rat, one treated
and one untreated. In control, the treated sponge was impreg-
noted with the amount of acetic acid necessary to impregnate
sponges with 5 my of Shea.
b) Values indicate means of weight gains in treated and entreat-
Ed sponges expressed as my dry weight.
c) Difference in mean change in dry weight is significant at
p <.05 by student's t-test.
EXAMPLE I
The polymer Shea is synthesized by polymerization of an
active divester at room temperature and under atmospheric
pressure. The starting material is Z-cHyp-OPcp, N-benzyloxy-
carbonless-) and O-pentachlorophenyl-(-OPcp) substituted
derivative of cis-4-hydroxy-L-proline (chop). Z-cHyp-OPcp
(5 g, 9.7 moles) is dissolved in 50 ml of dichloromethane and
reacted with 150 ml of isobutylene and 0.5 ml of concentrated
HOWE at room temperature for 4 days. The solution is neutralized
with triethylamine and evaporated in vacua. The residue is
dissolved in chloroform and washed with 5% sodium bicarbonate and
water. The chloroform layer is dried over sodium sulfate and
evaporated under reduced pressure. The crystalline residue is
1239393
67854-4
recrystallized from methanol to yield 5.05 g. The product
Z-cHyp (But)-OPcp (2.28 g, 4 moles), thus obtained is dissolved
in 4 ml of dim ethyl formamide and then Z-cHyp-OH (1.06 g, 4
moles), triethylamine (0.56 ml, 4 moles) and imidazole
(272 my, 4 moles) are added. The mixture is left to stand at
room temperature for 2 days, evaporated in vacua, and the residue
is purified by silica-gel column chromatography to obtain an
oily product.
The product thus obtained is dissolved in 30 ml of
ethyl-acetate and 30 ml of tetrahydrofuran, and pentachlorophenol
(931 my, 3.5 moles) and dicyclohexylcarbodiimide (721 my, 3.5
moles) are added. The mixture is allowed to stand for 15 ho,
and the precipitate is removed by filtration and the solution is
evaporated. The residue is recrystallized from chloroform and
methanol. The yield is 2.17 g. The product thus obtained is
treated with tri-fluoroacetic acid for 60 mint and then
evaporated. The residue is polymerized by dissolving in 4 ml of
dimethylformamide with triethylamine, and imidazole (170 my, 2.5
mole) for 7 days. The solution is evaporated. The residue is
dissolved in 30 ml of acetic acid and 30 ml of methanol and
subjected to catalytic hydrogenation over palladium-charcoal for
8 his. The catalyst is removed by filtration and the filtrate
concentrated. The residue is dissolved in dichloromethane and
ether is added to give 390 my of amorphous powder.
EXAMPLE IV
The polymer Shea is synthesized by polymerization of
an active ester with imidazole at elevated temperature and under
reduced pressure. Z-cHyp-OPcp (3 g, 5.8 moles) is dissolved in
2 ml of dimethylformamide and reacted with 5 molar equivalents
of imadazole at 110C. in vacua for 7 days. The oily precipitate
-16
I
~239393
67854-4
obtained is washed with methanol to remove excess imidazole, and
is then dissolved in 10 ml of dimethylformamide. The solution
is saturated with an hydrous ammonia to amid ate the carboxyl-
terminal residue, and evaporated. The residue is dissolved in
acetic acid and dimethylformamide, and subjected to catalytic
hydrogenation over palladium-charcoal for 2 days. The catalyst
is removed by filtration and the filtrate is concentrated. The
residue is dissolved in acetic acid and dialyzed against 50~ of
acetic acid for 1 day. The contents of the bag are lyophilized
to give 1.8 g of amorphous powder.
EXAMPLE V
The polymer crag is synthesized from N-benzyloxycarbon-
yl-substituted chop (Boc-cHyp-OH) and L-alanine (Buckley), and
from O-benzyl-glycin (GlyOBzl). To a solution of GlyOBzl-p-
toluenesulphonyl (1.3 g, 4 moles) and triethylamine (0.56 ml,
4 moles) in 10 ml tetrahydrofuran, Boc-cHyp-OH (0.85 g, 3.7
moles) and dicyclohexylcarbodiimide (0.76 g, 3.7 moles) are
added. The mixture is allowed to react for 15 hr. The
precipitate is removed by filtration and the filtrate is
concentrated to a residue which is then dissolved in ethyl acetate.
The solution is washed with N-hydrochloric acid, I sodium
bicarbonate, and water. It is dried over sodium sulfate and
evaporated in vacua. The residue is recrystallized from
ethyl acetate and Nixon to obtain 1.02 g.
The product thus obtained is treated with trifler-
acetic acid for 40 mix and evaporated. The residue is dissolved
in 3 ml of dimethylformamide, and triethylamine and the N-
hydroxy-succinimide derivative of Buckley, Buckles
(715 my, 2.5 moles), are added. The mixture is allowed to
react for 2 days and evaporated. The residue is dissolved in
-aye-
I
~239393
67854-4
ethyl acetate and the solution is washed with 1 N Hal, I
sodium bicarbonate, and water. It is dried over sodium sulfate
and evaporated. The residue is recrystallized from ethyl acetate
and Nixon to obtain 950 my. The product obtained is dissolved
in methanol and subjected to catalytic hydrogenation over
palladium-charcoal for 6 his. The catalyst is removed by
filtration and the filtrate is concentrated to a residue which
is recrystallized from ethyl acetate and Nixon to yield 840 my.
The product is dissolved in 5 ml of dimethylformamide,
and Z-cHp(But)-OPcp (1.31 g, 2.3 mole) and imidazole (96 my,
2.3 mole) are added. The mixture is allowed to react for 2 days,
evaporated in vacua, and the residue is purified by column
chromatography on silica gel to yield 940 my.
The product is dissolved in 10 ml of ethyl acetate and
10 ml of tetrahydrofuran, and Pcp-OH (373 my, 1.4 mole) and
dicyclohexylcarbodiimide (310 my, 1.5 mole) are added. The
mixture is allowed to react for 15 ho, and evaporated in vacua.
The residue is purified by column chromatography to yield 1.0 g.
The product thus obtained is treated with trifler-
acetic acid for 40 mix and evaporated in vacua. The residue is
polymerized by dissolving 2 ml of dimethylformamide and in-
ethyl amine for 7 days and evaporated in vacua. The residue is
dissolved in 10 ml of acetic acid and 10 ml of methanol, and
subjected to catalytic hydrogenation over palladium-charcoal for
6 his.
The catalyst is removed by filtration and filtrate is
concentrated. The sample is then dissolved in acetic acid and
dialyzed against water for 1 day to obtain 140 my. of amorphous
powder.
While the invention has been described in connection
-16b-
Jo .,
1239393 67854-4
with several exemplary embodiments thereof, it will be
understood that many modifications will be apparent to those
of ordinary skill in the art; and that this application is
intended to cover any adaptations or variations thereof. There-
fore, it is manifestly intended that this invention be only
limited by the claims and the equivalents thereof.
-16c-
